ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report

Case Report: Nitrofurantoin-induced interstitial lung disease

[version 1; peer review: 1 approved, 1 not approved]
PUBLISHED 01 Apr 2015
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Nitrofurantoin is widely used for urinary tract infection (UTI) prophylaxis. Long-term use is known to be able to cause serious adverse effects including pulmonary and hepatic toxicity. The prevalence of nitrofurantoin-induced pulmonary injury is on the increase again as the drug regains popularity as a urinary antiseptic.
We describe a previously healthy 83-year-old woman who presented to our emergency department in early 2012 with progressive dyspnoea since two weeks. This was not preceded by cough. She had no fever, wheezing, chest pain, or sputum production. She was a 50 pack per year ex-smoker. She had no previous exposure to tuberculosis or industrial chemicals. However, she suffered from recurrent symptomatic UTIs and was on a long-term prescription of nitrofurantoin for prophylaxis.
Respiratory examination revealed dullness on percussion at both lung bases and widespread fine inspiratory crackles throughout both lungs. Arterial blood gas analysis showed hypoxia and complete compensation of respiratory acidosis.
Initial treatment with co-amoxiclavulanic acid was initiated. CT scanning of the chest showed widespread ground-glass appearance in both lungs with organising pneumonia. A diagnosis of nitrofurantoin-induced interstitial lung disease (NIILD) was suspected. Nitrofurantoin was subsequently stopped and prednisone treatment at 30 mg OD was initiated. Follow-up chest X-ray showed marked improvement.

Keywords

Nitrofurantoin, urinary tract infection, pulmonary injury nitrofurantoin-induced interstitial lung disease, NIILD

Case report

A previously healthy 83-year-old Caucasian woman presented with progressive dyspnoea. She was a 50 pack per year ex-smoker. She suffered from recurrent symptomatic urinary tract infections (UTIs) and was prescribed long-term nitrofurantoin 50 mg daily for prophylaxis by her GP.

On examination she appeared dyspnoeic. She was afebrile and normotensive with respiratory rate of 31 per minute and oxygen saturation was 91% while receiving supplementary oxygen at a flow of 5 liter per minute. Respiratory examination revealed fine inspiratory crackles throughout both lungs. Arterial blood gas showed hypoxia with PaO2 5.4 kPa (without oxygen suppletion), PaO2 8.3 kPa (with 5 liter/min oxygen suppletion) and complete compensation of respiratory acidosis with pH 7.37, and PaCO2 6.9 kPa on 5 liter oxygen suppletion with base excess 2.9 mmol/l [Figure 1]. Laboratory findings showed increased leucocytes and C-reactive protein level [Figure 2]. Auto-immune laboratory findings including the antinuclear antibody and rheumatoid factor tests were negative. Chest X-ray revealed diffuse bilateral interstitial infiltrates [Figure 3]. CT scanning of the chest showed widespread ground-glass appearance with organizing pneumonia [Figure 4]. Initial treatment with co-amoxiclavulanic acid was started at a dose of 1.2 gram 4 times daily.

69586093-06da-4462-b15d-5da26262b721_figure1.gif

Figure 1. The course of FiO2/PaO2 (y axis) during admission days (x axis).

69586093-06da-4462-b15d-5da26262b721_figure2.gif

Figure 2. The course of C-reactive protein (CRP)/leucocytes (y axis) during admission days (x axis).

69586093-06da-4462-b15d-5da26262b721_figure3.gif

Figure 3. Chest X-ray on admission showed diffuse bilateral interstitial infiltrates on both sides.

69586093-06da-4462-b15d-5da26262b721_figure4.gif

Figure 4. High-resolution computed tomography (HRCT) on admission showed widespread ground-glass appearance with organizing pneumonia.

Course

Nitrofurantoin was subsequently stopped and prednisolone treatment at 30 mg OD was initiated. She had a short hospital course of 12 days and was finally discharged without long term oxygen treatment. Follow up chest X-ray before discharge and after withdrawal of nitrofurantoin (Figure 5) showed marked improvement compared to the X-ray upon admission.

69586093-06da-4462-b15d-5da26262b721_figure5.gif

Figure 5. Chest X-ray before discharge and after nitrofurantoin withdrawal.

The patient was seen after two months during outpatient control; her symptoms had improved dramatically and a follow-up chest X-ray showed further normalization.

Discussion

The differential diagnosis of nitrofurantoin induced interstitial lung disease (NIILD) includes pulmonary edema, cryptogenic organizing pneumonia and idiopathic interstitial pneumonias1. The auto-immune markers tested, antinuclear antibody and rheumatoid factor, were negative indicating a reaction to nitrofurantoin rather than an underlying systemic pathology.

Prompt resolution following the discontinuation of nitrofurantoin further supports the diagnosis2,3. The diagnosis is based on the history of nitrofurantoin use and the absence of another explanation for the patient’s symptoms and radiographic abnormalities.

Discontinuation of nitrofurantoin results in the regression of symptoms and radiographic abnormalities3. Systemic corticosteroids are occasionally administered and it remains unclear how much corticosteroids contribute to improvement beyond drug cessation alone4.

Conclusion

Long-term use of nitrofurantoin as prophylaxis for UTIs can cause serious pulmonary side effects. Our patient received antibiotics and corticosteroids because of diagnostic uncertainty. This may represent frequent clinical practice, however there are no specific symptoms to separate NIILD from other interstitial lung diseases1.

Informed consent

Written informed consent for publication of clinical details and clinical images was obtained from the next of kin.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 01 Apr 2015
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Basunaid S, Pilate H, Schoutteten M and Sprooten R. Case Report: Nitrofurantoin-induced interstitial lung disease [version 1; peer review: 1 approved, 1 not approved]. F1000Research 2015, 4:85 (https://doi.org/10.12688/f1000research.6245.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 01 Apr 2015
Views
13
Cite
Reviewer Report 03 Sep 2015
Klaus Dalhoff, Medizinische Klinik III, Pulmologie, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany 
Approved
VIEWS 13
A case of drug-induced ILD after Nitrofurantoin Treatment due to recurrent UTIs is presented. Although there are some questions left (DD pulmonary infection, documentation on the CT scan shown) the report seems plausible. This is an important topic since NF use ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Dalhoff K. Reviewer Report For: Case Report: Nitrofurantoin-induced interstitial lung disease [version 1; peer review: 1 approved, 1 not approved]. F1000Research 2015, 4:85 (https://doi.org/10.5256/f1000research.6700.r10196)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
40
Cite
Reviewer Report 23 Apr 2015
Demosthenes Bouros, Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandropoulos, Greece 
Vasilios Tzilas, Academic Department of Pneumonology, University of Athens, Athens, Greece 
Not Approved
VIEWS 40
The authors describe a case of Nitrofurantoin-induced interstitial lung disease. However a lot of important data are missing from this review.
  1. The authors do not report the duration of nitrofurantoin therapy. This is of utmost importance as there are 3 types
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Bouros D and Tzilas V. Reviewer Report For: Case Report: Nitrofurantoin-induced interstitial lung disease [version 1; peer review: 1 approved, 1 not approved]. F1000Research 2015, 4:85 (https://doi.org/10.5256/f1000research.6700.r8203)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 22 May 2015
    Suhail Basunaid, Mayo University Hospital,, Ireland
    22 May 2015
    Author Response
    Thank you very much for the feedback regarding this case report.
    1. Our patient had nitrofurantoin therapy several times for a recurrent UTI. The last one was longer than normal. I am
    ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 22 May 2015
    Suhail Basunaid, Mayo University Hospital,, Ireland
    22 May 2015
    Author Response
    Thank you very much for the feedback regarding this case report.
    1. Our patient had nitrofurantoin therapy several times for a recurrent UTI. The last one was longer than normal. I am
    ... Continue reading

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 01 Apr 2015
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.